Shenzhen Fosun Kairos Biotechnology Co., Ltd. clinical trials

Acquired by Fosun Pharma

The registry lists 3 studies whose lead sponsor is Shenzhen Fosun Kairos Biotechnology Co., Ltd.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 14, 2026.

Status

Not yet recruiting: 2
Recruiting: 1

Phase

Phase 2: 2
Phase 1: 2
Early Phase 1: 1

Where

China: 3

Registry sponsor names on this page

Shenzhen Fosun Kairos Biotechnology Co., Ltd.3 studies

Something wrong with this grouping? Tell us on the Fosun Pharma page.

Studies

Recruiting first, then most recently updated. Showing 3 of 3. All Fosun Pharma studies →

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL AmyloidosisNot yet recruitingNCT07765524Phase 1/2
Sponsor listed in the registry: Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Shenzhen Fosun Kairos Biotechnology Co., Ltd. — acquired company within the Fosun Pharma group
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous NephropathyNot yet recruitingNCT07765537Phase 1/2
Sponsor listed in the registry: Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Shenzhen Fosun Kairos Biotechnology Co., Ltd. — acquired company within the Fosun Pharma group
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.RecruitingNCT07606937Early Phase 1
Sponsor listed in the registry: Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Shenzhen Fosun Kairos Biotechnology Co., Ltd. — acquired company within the Fosun Pharma group